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Introduction:  Acellular nerve allografts are viable treatment modality for bridging nerve gaps. 
Several small studies have demonstrated equal results to autologous grafts, however there is 
lacking information regarding outcomes for wider indications.  The aim of this retrospective case 
series was to evaluate the outcomes of patients treated with a nerve allograft in a variety of clinical 
situations. 
Methods: A retrospective chart analysis was completed between April 2009 – October 2017. The 
inclusion criteria for this study were: age ≥ 18 years at the time of surgery and be treated with a 
nerve allograft. Patients were excluded if they had not been followed-up for a minimum of six 
months. The modified Medical Research Council Classification (MRCC) was used to monitor 
motor and sensory changes in the post-operative period. 
Results: 207 nerve allografts were used in 156 patients; of these 129 patients with 171 nerve 
allografts fulfilled the inclusion criteria. 77% of patients achieved a sensory outcome score of S3 
or above and 36% achieved a motor score of M3 or above.  All patients with chronic pain had 
improvement of their symptoms. 
Discussion: Graft length and diameter were negatively correlated with reported outcomes. One 
patient elected to undergo revisional surgery and the original graft was shown histologically to 
have extensive central necrosis. Anatomically, allografts used for lower limb reconstruction 
yielded the poorest results. All chronic patients had a significantly lower post-operative 
requirement for analgesia and allografts are effective in not only reducing pain, but also restoring 
a functional level of sensation. 
Conclusion: This study supports the wider application of allografts in managing nerve problems 










There is no uniform consensus of the best method to bridge the gap resulting from peripheral nerve 
injury (1-5); the available options include autologous grafts, synthetic or autologous conduits and 
allografts. In cases where a tensionless end-to-end neurorrhaphy is not possible, nerve repair with 
autologous nerve grafts remains the gold standard (5-8). However, harvesting an autologous nerve 
graft can lead to significant donor site morbidity: sensory loss, neuroma and scar formation have 
all been reported (9-13). As a consequence, alternatives such as synthetic nerve conduits or 
acellular nerve grafts have been developed however, these are only recommended nerve gaps up 
to 3 cm (4). De-cellularized allografts have been processed to remove cellular material from the 
graft whilst preserving the structural architecture (14).  Arguments against the efficacy of allografts 
cite that beneficial growth factors and supportive cells have been eradicated; this restricts their use 
to short nerve gaps (<3cm)(15).  
Neuropathic pain resulting from a peripheral nerve injury is relatively common in upper and lower 
extremity injuries being reported in up to a third of patients (16).  Despite immediate surgical 
repair of the nerve lesion it is unpredictable whether a patient will go on to develop neuropathic 
pain (16-18).  Pharmacological treatment with non-steroidal anti-inflammatory drugs, 
anticonvulsants, antidepressants, opioids and topical anaesthesia are the mainstay of treatment (19-
23).  Surgical intervention is generally advocated after non-operative treatment modalities have 
failed or where a clear pathological cause is identified (24).  Surgery for neuromas is well 
established and associated with mixed outcomes (25, 26) and an ideal surgical strategy has not 
been identified.  Surgical treatment is targeted at finding an alternative, less problematic, 
environment for the nerve to regenerate within including muscle, bone, graft and vein. Studies 
examining the effect of targeting reinnervation of symptomatic neuromas to specific receptors 
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painful nerves may be considered as an attempt to heal a nerve, rather than to hide it and has been 
shown to be most beneficial compared to all other types of neuroma treatments (28). 
The purpose of the study is to review the outcomes of all nerve injuries that were treated with 
allografts in a single institution and compare these with existing published reports. If the results of 
nerve allografts are equal or even superior to alternative techniques it supports their use and avoids 
secondary complications at the donor site. This series encompasses the repair of sensory and mixed 
nerves in both the acute and chronic setting thus providing a comprehensive overview of outcomes. 
Materials and methods: 
Data was collected retrospectively for all patients whom received an Avance® allograft (AxoGen 
Inc., Alachua, FL) from 1st April 2009 to 31st October 2017 using the electronic patient record. 
The inclusion criteria were: age ≥ 18 years at the time of surgery and be treated with a nerve 
allograft. Patients were excluded if they had an alternative nerve repair technique or had not been 
followed-up for a minimum of six months.  Nerve defects were reconstructed by the available 
length and diameter of nerve allografts that best matched to the defect. 
All patients were assessed pre- and post-operatively by either an experienced hand surgeon or 
therapist. The modified Medical Research Council Classification (MRCC) (29, 30) was used to 
monitor motor and sensory changes during the post-operative period that included two point 
discrimination testing (2-PD) and motor recovery; this was chosen as the majority of similar 
studies use this as an outcome measure (31).  Where appropriate, the numeric rating scale (NRS) 
was used to record subjective pain scores.  Further assessment using Semmes Weinstein 
monofilament (SWMF) testing was used to map the sensory areas affected and to monitor the 
development during the recovery period (32-34).  All patients were operated on by a hand surgeon 
who had undertaken a specialist hand surgery fellowship. Intra-operatively in all cases, if a tension-
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interpositional graft was indicated and the surgeon opted to reconstruct the gap with a nerve 
allograft. 
Patients were separated into three categories of nerve injury: acute, delayed and chronic.  This 
classification was determined by the time taken from initial injury to the date of surgery. Patients 
presenting less than six weeks following injury, were defined as the ‘Acute Nerve Injury’ group. 
Patients presenting more than six weeks but less than six months following injury were defined as 
the ‘Delayed Nerve Injury’ group. Lastly, patients presenting later than six months following 
injury were defined as the ‘Chronic Nerve Injury’ group; these patients presented with either 
chronic pain or allodynia. Patients with a static mechanical allodynia were tested with 
allodynography in combination with a rainbow pain scale (35) to map the localization and severity 
of the hypersensitive territory (Fig. 1). All patients in the chronic nerve injury group had ultrasound 
guided local anaesthesia injections carried out on at least two separate pre-operative occasions to 
confirm the diagnosis of a localized neurogenic pain prior to surgical intervention. 
Ethical approval for the study was obtained from the regional Ethical Committee and informed 
consent for all patients was obtained prior to surgical intervention. Statistical analysis using 
unpaired Student’s t-tests was performed using GraphPad Prism (version 7.00 for Windows, 
GraphPad Software, La Jolla California USA) to compare different groups of the study and linear 
regression calculations were used to analyse relationships between patient and allograft 
characteristics and clinical outcomes; significance was attributed to results where p ≤0.05. 
Results: 
2,499 nerve injuries in 1,475 patients were operated on between 1st April 2009 and 31st October 
2017. 1,580 primary neurorrhaphies were completed in 1,188 patients, 207 nerve allografts were 
used in 156 patients and that 80 patients were treated with a combination of primary repairs and 
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primary nerve repairs and 36 nerve grafts in 27 patients were excluded: 8 patients were under the 
age for licenced use and 19 patients were lost to follow-up, of these 16 were from the acute injuries, 
2 from delayed injuries and 1 from a chronic neuroma (Fig. 2). 135 nerve grafts were used in 94 
patients to treat acute nerve injuries with at a mean age at surgery of 45 years (range 18 – 82 years) 
with an average follow-up of 13 months (range 6 – 38 months). The mean length and diameter of 
the allografts used were 27 mm (range 8 – 100 mm) and 2 mm (range 1 – 5 mm) respectively. 77% 
of patients achieved a sensory outcome score of S3 or above and 36% achieved a motor score of 
M3 or above; scores above these levels are deemed to have meaningful recovery (36). A summary 
of the acute nerve injury results can be seen in Table 1. 
Graft length, diameter and anatomical location were the only factors which statistical significance 
could be attributed to.  Patients were allocated to one of four groups according to the length of 
graft used. The shorter length graft had significantly better outcomes than longer graft groups and 
grafts used in lower limbs had significantly poorer outcomes than either those used in the hand or 
upper limb (p < 0.05) (Figs. 3&4). Similarly, an increase graft diameter was associated with a 
significant reduction in outcome (p<0.05). Significant differences were seen in the outcomes of 
the type of sensory nerves reconstructed; pure sensory nerves yielded better sensory outcomes than 
the sensory component of mixed nerves.  The impact of patient age, the mechanism of injury and 
if individuals with multiple nerve injuries was analysed but no significance was demonstrated (Fig. 
4). One patient developed a surgical site infection requiring removal of the allograft; no other 
complications were noted. 
10 allografts were used in 10 patients to treat delayed nerve injuries. The mean age at surgery was 
40 years (range 18 – 77 years) with an average time between nerve injury and operation of 3 
months (range 2 – 6 months); the mean follow-up was 13 months (6 – 25 months). 70% of patients 
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above.  No significance was demonstrated between outcomes from acute nerve injuries and 
delayed nerve injuries. 
26 allografts were used in 25 patients (19 male, 6 female) with neurogenic pain.  The mean age 
was 44 years (range 19 – 77 years) with an average time between nerve injury and operation of 3 
years (range 1 – 16 years); the mean follow-up was 12 months (6 – 49 months). 17 allografts were 
used to treat upper limb neuropathic pain, of which six were digital nerves. Nine allografts were 
used for lower limb neuropathic pain. 18 allografts were used to treat injuries resulting from sharp 
lacerations, six from crush injuries and two from tumour resections. Overall, the mean diameter 
and length of allografts used was 3 mm (range 1 – 5 mm) and 37 mm (range 8 – 75 mm) 
respectively.  There was no significant difference in lengths of allografts used in upper limb in 
comparison to lower limb, however the diameter of allografts used in the upper limb was 
significantly smaller (p < 0.05).  A summary of this data can be seen in Table 2. 
The median pre-operative NRS pain score was 7 (range 3 - 10) in comparison to the post-operative 
score of 3 (range 0 - 7); t-test statistical analysis revealed this to be a significant reduction in pain 
score (p < 0.05). Prior to surgical intervention 17 out of the 26 patients were taking regular 
medication for symptoms.  Postoperatively this was significantly reduced to six patients (p < 0.05) 
with the category of non-steroidal anti-inflammatory drugs being most affected (p < 0.05) (Fig. 5). 
Similarly, there was a significant improvement in sensation; the pre-operative mean was S1 on the 
MRCC scale in comparison to S3 post-operatively (p < 0.05) and 57% of patients had a meaningful 
recovery of sensation following surgery.   
Ten patients had symptoms of allodynia pre-operatively and all of these reported improvement in 
their symptoms on the rainbow scale from severe to none (0.03 g to 15 g) and had a significant 
reduction in the size of the affected area postoperatively (p < 0.05) (Fig. 1). Three patients had 
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severity had not worsened.  A summary of this data can be seen in Table 3.  No patients developed 
a higher level of pain or a diminished level of sensation following surgical intervention.  
Discussion: 
The purpose of this study was to review a single centre’s use of nerve allografts in a variety of 
nerve injuries.  171 nerve allografts were included in this retrospective case series with patients 
grouped into acute, delayed and chronic nerve injuries.  The inherent limitations of retrospective 
case series apply to this study as there is no control group, patient variables cannot be controlled 
and the vulnerability of bias all weaken the strength of any interpretations of these results.   
Differences in outcomes based on anatomical distribution: 
There is sufficient experimental data in this study to suggest that allografts yield results at least 
equal to autologous grafts supporting previous published reports (7, 30, 37-40). In an attempt to 
standardize variables, patients were grouped by age, mechanism of injury and anatomical location. 
In this series 84% of hand injuries had a meaningful level of recovery; this is comparable to similar 
studies in the literature (30, 31, 38-44) and re-confirm that allografts are a reliable option for 
managing digital nerve gaps (31, 42, 45, 46). Analysing outcomes based on anatomical region 
revealed that allografts used in the lower limb yielded the poorest outcomes. There was no 
statistical difference in allograft dimensions between the upper limb and lower limb groups, 
suggesting that allograft use in the lower limb may be independent prognostic factor. There are no 
published reports directly comparing the outcomes of upper and lower extremity nerve injuries 
however, the literature reporting lower limb outcomes following nerve grafting range from 14 – 
75% with nerve gaps greater than 6 cm having significantly worse outcomes (47-51); the results 
of this study fall within this range. The literature reports that peripheral nerve lesions in the upper 
limb are not only more common but also have better outcomes when treated with nerve grafts (39 
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the hand 22 mm, which are longer than all published reports except one where the mean length 
was 79 mm (52); these grafts were confined to brachial plexus injuries.  From our results, it would 
appear that more proximal nerve injuries yielded the poorest results possibly as a consequence of 
the distance the axons have to regenerate.  This is well documented in the brachial plexus literature 
(52) and perhaps accounts for the poorer outcomes associated with lower limb injuries as 
regeneration must also occur over greater distances. It was interesting to demonstrate a difference 
in outcomes between pure sensory nerves and the sensory component of mixed nerves; this has 
not been described in the literature but may be explained by incorrect alignment at a fascicular 
level when grafting mixed nerves. 
Effect of allograft parameters on outcomes: 
The most striking results in study were that both an increase in allograft length and diameter 
yielded a significantly poorer outcome.  Analysing the ungrouped data for graft-length 
demonstrated a significant negative correlation (p < 0.001, r = -0.36) between allograft length and 
outcome.  When separating graft size into < 30 mm and those > 30 mm, the shorter group had a 
significantly better outcome (p = 0.003). 26 allografts greater than 50 mm in length were used in 
this study with 54% yielding a meaningful recovery and in one case two 50 mm allografts were 
combined in series to bridge a 100 mm gap; this result is comparable to the autograft literature 
reporting between 50 and 84%. A recent publication by Hoben et al. (15) postulates that longer 
grafts show increased accumulation of senescent markers and our findings support this clinically.  
The results from our study suggest that nerve allografts are not the solution to bridging large nerve 
gaps, particularly in mixed nerves. The outcome for motor recovery sharply diminished in grafts 
that were more than 5 cm and for sensory nerves the trend was similar but not as severe. Although 
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this study certainly adds weight to draw concerns regarding the efficacy of bridging long mixed 
nerve gaps. 
An increased graft diameter was associated with a significantly poorer outcome. Overall, there was 
a significant negative correlation between diameter and outcome (p < 0.0001, r = -0.34) for all the 
data. Separating the results into those obtaining a meaningful recovery (n = 123) and those not (n= 
40), the group with a meaningful recovery had a statistically significant lower mean diameter (p = 
0.003).  Only two of the allograft studies reviewed in this paper commented on the diameter of the 
graft used and in both the reported diameter was less than 2mm.  In our study, allografts with 
diameters of up to 5 mm were used and the poorest outcomes were seen in larger diameter grafts, 
with > 3 mm in diameter appearing to be inhibitory to axonal regeneration.  Best et al. (53) 
demonstrated that in large diameter nerve grafts, scar formation as a sequelae to central ischaemia 
develops; this is likely to be the case with our results and has recently been reported in three cases 
(54). However, in comparison to autologous nerve grafts, the allograft is perhaps more sensitive.  
The heterogenous nature of the patient population has inherent limitations when attempting to 
draw a definitive conclusion however the data supports that a long, thick graft is associated with 
the poorest outcomes (39, 55, 56). In this series one patient failed to have a meaningful recovery 
at 18 months follow-up and elected to undertake revision surgery.  Initially the patient had 
reconstruction of their median nerve with a 50 mm x 4 mm allograft for chronic painful neuroma. 
The patient failed to have any improvement in their pain symptoms and at the time of revision the 
allograft was noted to be small and scarred. Histology confirmed that there was evidence of severe 
central necrosis with minimal evidence of successful axonal regeneration through the allograft 
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Mixed Nerve Outcomes: 
Twenty-five grafts were used to reconstruct mixed nerves. The mean diameter was 3.8 mm (range 
1 – 5 mm) and mean length was 41 mm (range 15 – 70 mm).  Eleven grafts yielded a meaningful 
sensory recovery (44%) and nine grafts yielded a meaningful motor recovery (36%).  The poorer 
results demonstrated with increased diameter size is likely a consequence of central ischaemia 
within the graft, resulting in scar formation (53, 57) blocking the pathway for the axons to 
regenerate; furthermore, there is additional competition between regenerating motor and sensory 
axons and the allograft scaffold no longer has sufficient physical channels to permit adequate 
regeneration.  The results suggest that in order to over-come this problem it may be better to use 
multiple smaller diameter grafts rather than one large diameter graft as this may reduce central 
ischaemia. Table 4 summarizes the literature cited and allows a succinct comparison between 
previously published studies. 
Chronic Pain Outcomes: 
There is currently one data series for the use of allografts for the treatment of chronic neurogenic 
pain reporting positive results in 26 patients in foot and ankle surgery (43, 58).  Although they 
report a similar reduction in pain symptoms, the unreliable assessment of pre-operative sensation 
in this patient group meant that the authors were unable to accurately comment on the restoration 
of sensation.  Surgical techniques based on burying or relocating nerve stumps are effective in 
improving the primary pain symptom (59-61) but there can be no effective recovery of sensation; 
this is particularly important when considering hand surgery or neuromas associated with 
amputations.  Our study has shown that allografts can not only significantly reduce pain symptoms 
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All patients were investigated pre-operatively with ultrasound.  Of the 26 patients, 11 were seen 
to have end-neuromas and 15 had neuromas-in-continuity; these findings were confirmed intra-
operatively.  In both cases, the neuroma was completely excised and the proximal and distal nerve 
stumps were debrided so that healthy fascicles were seen in the proximal stump and healthy 
vascularized nervous tissue was seen in the distal stump.  No statistically significant differences 
were demonstrated between the two groups (p = 0.43). 
Ten of the patients in this study reported symptoms of allodynia pre-operatively.  Although the 
results are insufficiently powered, every patient had a reduction in their symptoms, with some 
reporting complete resolution of hypersensitivity (Fig. 2).  By treating the cause of neurogenic 
pain, there was a significant reduction from 65% to 23% of patients requiring pain medication 
post-operatively.  Many of the medications used to treat chronic pain have adverse side effects 
such as drowsiness, inability to concentrate and the development of tolerance over time (62).  The 
results from this study suggest that by using allografts, patients required lower levels of pain 
medication; in the long-term this may help to improve their quality of life.  This finding cannot be 
taken in isolation as there are many confounding factors however, the results from this study 
warrant future prospective investigations into the benefits that allografts have in the management 
of pain in these patients. 
From our experience we find that the most important step in the management chronic pain patients 
with peripheral nerve lesions is establish the exact pathogenicity.  Time is required to precisely 
localize the source of the neurogenic pain and confirm that symptoms are not part of a diffuse 
central pain disorder.  Therefore, several attempts to stop the pain by local anaesthesia and or 
change the pain intensity or territory by somatosensory rehabilitation (35) helps predict which 
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response to surgery hence it is an important documentation tool in recording surgical outcomes 
and the incorporation of this into routine practice would be highly recommended (Fig. 7). 
Conclusion: 
The results of this case series support a wider application of allografts in clinical practice. The 
outcomes obtained with allografts are comparable to autologous nerve grafts in short defects; the 
problems encountered with increased graft length and diameter associated with autologous nerve 
grafts are seen with allografts. This study supports recent literature to suggest that allografts 
provide a reasonable alternative for short grafts in the clinical setting and can yield similar 
outcomes without the associated risks of harvesting autologous grafts from a second surgical site. 
However, caution must be applied when implementing their use in long nerve gaps that require 
large diameter allografts. A well-designed multi-centre randomized controlled trial is needed to 
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Figure 1:  Improvement of allodynia symptoms in patient CPG08. (Left) Pre-operative 
illustration of Semmes Weinstein monofilament testing demonstrating how light touch (0.03 g 
filament) could produce severe (red schematic) allodynia).  (Right) Two years post reconstruction 
demonstrates a drastic reduction in both the area (purple schematic) and the pressure (15 g 
monofilament) required to produce allodynia symptoms, this remained unchanged at four-year 
follow-up. 
Figure 2:  A flow-diagram to demonstrate the inclusion and exclusion criteria of the study, 
showing the groups the allografts were separated into. 
Figure 3: A scatter plot of MRCC outcomes against allograft length. There was a significant 
negative correlation (p < 0.05) associated with increased allograft length and outcome.  
Figure 4:  A summary of the statistical analysis results of the acute nerve injury group. (* p < 
0.05, ** p < 0.001). No statistical difference was demonstrated between age (Top, left), 
mechanism of injury (Top, right) and between patients with single versus multiple nerve injuries 
(Middle, left). Longer graft length groups had significantly pooper outcomes (Middle, right), 
allografts use in lower limb nerve injuries had poorer outcomes (Bottom, left) and sensory recovery 
in mixed nerves was significantly worse than pure sensory nerves (Bottom, right). 
Figure 5: A bar chart demonstrating the reduction in pain medication used pre- and post-






Copyright © American Society of Plastic Surgeons. All rights reserved.
22 
 
Figure 6: A failed allograft with histological findings. (Top, left) A 50 mm x 4 mm allograft 
was used to reconstruct a median nerve defect resulting from a large painful neuroma. (Top, right) 
At 18 months follow-up, the patient had no symptomatic improvement and elected to undertake 
revisional surgery. At the time of the surgery the clinical appearance of the allograft was similar 
to scarred tissue. (Bottom) Histological examination (H&E staining) demonstrated large areas of 
central necrosis with little evidence of axonal regeneration through the graft. 
Figure 7: Clinical example - restoration of sensory function.  (Top, left) A pre-operative 
photograph of the left medial malleolus.  The patient (CPG22) suffered a grade IIIb pilon fracture 
with secondary osteomyelitis of his tibia 18 months previously.  The defect had been covered with 
an osteocutaneous free scapular flap.  The lightning bolt demonstrates the trigger point for 
neuropathic pain.  (Top, right) Intra-operative photography depicting a gap in the tibial nerve after 
isolating the proximal and distal nerve stumps (red arrows).  (Center) An acellular allograft (green 
arrows) was used to bridge the defect. (d) Semmes Weinstein monofilament testing pre- (bottom, 
left) and one year post-operatively (bottom, right) showing improved sensation in the distribution 
of the tibial nerve. 
Table 1:A summary of the outcome of acute nerve injuries following treatment with nerve 
allograft. 
Table 2:A summary of the patients and allograft details for all subjects treated in the chronic pain 
group. (NRS – Numeric Rating Scale, MRCC - Medical Research Council Classification) 
Table 3:A summary of the sub-group of patients that exhibited symptoms of allodynia pre-
operatively.   







Copyright © American Society of Plastic Surgeons. All rights reserved.
23 
 
Table 1. Outcomes: Acute nerve injuries 

































Age (years)     
18 - 34 40 (30, 10) 23.9 (SD 3.6) 416 (SD 188) 33.5 (SD 20.6) 2.58 (SD 1.34) 26 10 4 30 10 13 21 5 1 70.0% 18.1% 
35 - 49 33 (29, 4) 41.9 (SD 6.0) 426 (SD 201) 27.0 (SD 16.6) 2.20 (SD 1.15) 26 3 4 26 7 12 16 5 0 78.8% 42.9% 
50 - 64 46 (39, 7) 57.0 (SD 4.4) 402 (SD 219) 21.8 (SD 8.09) 1.99 (SD 0.84) 38 4 4 39 7 15 25 3 3 84.1% 57.1% 
65+ 16 (16, 0) 73.9 (SD 5.2) 423 (SD 307) 22.5 (SD 13.7) 1.94 (SD 0.93) 15 1 0 15 1 3 11 2 0 68.8% 0% 
Gap Length (mm)       
5 - 14 20 (15, 5) 49.1 (SD 19.4) 409 (SD 98.0) 9.95 (SD 0.83) 1.60 (SD 0.50) 20 0 0 20 0 4 15 1 0 90.0% - 
15 - 29 49 (44, 5) 47.5 (SD 15.8) 387 (SD 200) 17.2 (SD 3.07) 2.00 (SD 0.74) 42 2 4 43 5 21 24 1 3 81.3% 66.7% 
30 - 49 48 (41, 7) 44.7 (SD 17.7) 362 (SD 190) 30.8 (SD 3.17) 2.09 (SD 1.13) 37 9 1 39 8 11 31 6 0 74.5% 37.5% 
50+ 18 (12, 6) 34.7 (SD 18.3) 661 (SD 270) 58.8 (SD 14.1) 3.65 (SD 1.27) 5 7 5 7 10 7 3 7 1 52.9% 10.0% 
Anatomical Location       
Hand 105 (92, 13) 46.9 (SD 17.6) 384 (SD 207) 22.3 (SD 10.6) 1.74 (SD 0.66) - - - 105 0 30 63 12 0 83.8% - 
Upper Limb 18 (11, 7) 36.9 (SD 16.6) 479 (SD 184) 44.8 (SD 23.8) 4.01 (SD 0.84) - - - 5 12 7 8 3 0 72.2% 25.0% 
Lower Limb 12 (11, 1) 41.2 (SD 15.5) 610 (SD 208) 37.5 (SD 18.0) 3.42 (SD 0.99) - - - 0 12 6 2 0 4 25.0% 41.7% 
Mechanism of Injury       
Crush 41 (37, 4) 43.6 (SD 16.7) 441 (SD 184) 28.8 (SD 19.1) 2.54 (SD 1.14) 28 7 6 31 10 - - - - 70.7% 30.0% 
Laceration 73 (65, 8) 46.6 (SD 18.1) 339 (SD 158) 22.5 (SD 10.9) 1.97 (SD 0.94) 63 8 2 65 8 - - - - 83.7% 25.0% 
Avulsion 15 (7, 8) 40.9 (SD 19.1) 643 (SD 287) 42.3 (SD 19.0) 2.27 (SD 1.53) 12 3 0 12 3 - - - - 80.0% 33.3% 
Other 4 (3, 1) 55.7 (SD 5.32) 656 (SD 308) 26.3 (SD 16.0) 2.75 (SD 1.50) 0 0 4 0 4 - - - - 0.0% 75.0% 
       
All Acute Data 135 (114, 21) 45.1 (SD 17.6) 417 (SD 214) 26.6 (SD 16.0) 2.19 (SD 1.11) 105 18 12 110 25 43 73 15 4 77.0% 36.0% 
 
a Report in mean  Standard Deviation (SD) 













































CPG01 M 39 610 195 7 0 S0 S3+  ✔   Superficial peroneal n. 3.5 30 
CPG02 M 52 354 48 7 5 S1 S2   ✔  Superficial radial n. 3 70 
CPG03 F 27 382 > 3 yrs 5 0 S3 S4    ✔ 5th Radial digital n. 1.5 30 
CPG04 M 49 525 891 9 3 S0 S3+  ✔   Dorsal ulnar n. 3 30 
CPG05 M 19 362 826 6 0 S1 S4  ✔   Genito-femoral n. 3 30 
CPG06 F 48 356 748 8 3 S0 S3 ✔ ✔   Superficial peroneal n. 2 50 
CPG07 M 60 385 242 9 4 S0 S2 ✔ ✔   Saphenous n. 3 50 
CPG08 M 30 1504 2556 10 2 S1 S2 ✔  ✔  2nd Radial digital n. 3 30 
CPG09 M 44 476 973 7 6 S1 S3+ ✔  ✔  Medial brachial cutaneous n. 3 60 
CPG10 M 39 389 161 8 0 S1 S3+  ✔   Superficial radial n. 3 15 
CPG11 M 40 354 4440 9 4 S0 S2 ✔ ✔   Superficial ulnar n. 2 40 
CPG12 M 42 297 102 3 0 S1 S4  ✔   4th Radial digital n. 1.5 8 
CPG13 M 46 285 667 9 4 S0 S2 ✔  ✔  4th Ulnar digital n. 1.5 45 
CPG14 M 56 383 5968 6 3 S0 S3  ✔   Superficial radial n. 3 20 
CPG15 M 77 377 102 5 0 S1 S2  ✔   Median n. (sensory) 3 30 
CPG16 F 47 300 696 8 7 S0 S3 ✔ ✔   1st Ulnar digital n. 1.5 15 
CPG17 F 47 300 696 8 7 S0 S3 ✔ ✔   2nd Ulnar digital n. 1.5 15 
CPG18 M 47 360 378 5 0 S1 S3  ✔   Superficial radial n. 2 50 
CPG19 M 36 180 306 5 5 S0 S0  ✔   Superficial radial n. 3 40 
CPG20 F 51 400 601 9 4 S0 S2 ✔ ✔   Inferior medial genicular n. 2 15 
CPG21 M 48 360 42 5 0 S1 S3  ✔   Dorsal ulnar n. 3 15 
CPG22 M 37 420 565 5 0 S0 S2   ✔  Tibial n. 5 70 
CPG23 F 60 355 2896 7 4 S1 S2    ✔ Median n. (sensory) 3 75 
CPG24 F 18 220 1290 8 2 S1 S3   ✔  Tibial n. 4 70 
CPG25 M 50 360 330 7 6 S0 S2 ✔ ✔   1st Radial digital n. 2 25 
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Patient Details  
Nerve affected 
Pre-Operative Assessment Post-Operative Assessment Total area 
reduction 
(%) 









CPG06 F 48 356 Superficial peroneal n. Green 1.5 - - 100 
CPG07 M 60 385 Saphenous n. Blue 3.6 - - 100 
CPG08 M 30 1504 2nd Radial digital n. Violet 15 Blue 3.5 95 
CPG09 M 44 476 Medial brachial cutaneous n. Violet 15 - - 100 
CPG11 M 40 354 Superficial ulnar n. Violet 15 - - 100 
CPG13 M 46 285 4th Ulnar digital n. Violet 15 - - 100 
CPG16 F 47 300 1st Ulnar digital n. Blue 3.6 - - 100 
CPG17 F 47 300 2nd Ulnar digital n. Blue 3.6 - - 100 
CPG20 F 51 400 Inferior medial genicular n. Indigo 8.7 Indigo 8.7 0 
































Sensory Mixed Motor Sensory Mixed Motor 
This study 135 45 ± 18 417 ± 214 27 ± 16 2 ± 1 105 18 12 110 25 - 77  36 
Brooks et al. 
(41) 
76 41 ± 17 264 ± 152 22 ± 11 - 60 32 3 49 18 9 89 77 86 
He et al. 
(55) 
72 33 ± 11 180 18 ± 8 1.5 ± 0.5 72 - - 72 - - 72 - - 
Cho et al. 
(44) 
51 44 ± 16 296 ± 160 23 ± 12 - 35 16 - 35 13 3 86 - 80 
Rinker et al. 
(46) 
37 43 480 11 ± 3 - 37 - - 37 - - 92 - - 
Taras et al. 
(40) 
18 39 ± 19 455 ± 138 11 ± 7 - 18 - - 18 - - 100 - - 
Safa et al. 
(31) 
14 34 360 30 - - 14 - - 14 - - 86 - 
Squintani et al. 
(52) 
14 33 ± 12 720 79 ± 39 - - 14 - - - 14 - - 100 
Karabekmez et al. 
(39) 
10 43 ± 15 255 ± 85 2 ± 1 2 ± 0.5 10 - - 10 - - 100 - - 
Ducic et al. 
(45) 
8 46 ± 18 130 ± 90 18 ± 8 - - 8 - - - - -* - - 
Guo et al. 
(56) 
5 29 ± 8 396 ± 48 23 ± 4 2 ± 0 5 - - 5 - - 100 - - 
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aReport in mean ± Standard Deviation (SD)            
ᵇ Meaningful Recovery defined as having a score of S3-S4 or M3-M5 according to the modified MRCC outcome      
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